Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820612 | 0.90 | GRIN2B (0.44) | F2RALDH1A1GAAATMGRIN2B | |
| SCHEMBL751371 | 0.85 | GRM5 (0.41) | GRIN2B | |
| SCHEMBL8466706 | 0.83 | GRIN2B (0.39) | GRIN2BGRIN1 | |
| SCHEMBL3721445 | 0.82 | MAPT (0.45) | GRIN2BGRIN1 | |
| SCHEMBL9102020 | 0.82 | ACP3 (0.54) | F2RALDH1A1GAAATMGRIN2B | |
| SCHEMBL30836028 | 0.81 | KMT2A (0.43) | GAAL3MBTL1 | |
| SCHEMBL3728507 | 0.81 | NPSR1 (0.38) | ALDH1A1 | |
| SCHEMBL17021449 | 0.81 | KMT2A (0.43) | GAAL3MBTL1 | |
| SCHEMBL13840878 | 0.80 | ALDH1A1 (0.52) | F2RALDH1A1GAAATMGRIN2B | |
| SCHEMBL1832383 | 0.74 | ACP3 (0.60) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136137-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090069383-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1294714-B1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1764366-A2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076088-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | F2R 4/4885ALDH1A1 3883/4885GAA 3772/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | F2R 4/4885ALDH1A1 3033/4885GAA 3988/4885 |
| US-20090069383-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | F2R 4/4885ALDH1A1 3883/4885GAA 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.